Controlled Ovarian Stimulation

Women's Health
1
Pipeline Programs
1
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Ferring Pharmaceuticals
Ferring PharmaceuticalsArgentina - Buenos Aires
5 programs
1
FE 999302Phase 21 trial
Follitropin DeltaN/A1 trial
Follitropin DeltaN/A1 trial
Follitropin DeltaN/A1 trial
REKOVELLE®N/A1 trial
Active Trials
NCT04503707Completed250Est. Oct 2021
NCT03393780Completed1,018Est. Jul 2020
NCT03697031Terminated362Est. Dec 2020
+2 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Ferring PharmaceuticalsFE 999302
Ferring PharmaceuticalsREKOVELLE®
Ferring PharmaceuticalsFollitropin Delta
Ferring PharmaceuticalsFollitropin Delta
Ferring PharmaceuticalsFollitropin Delta

Clinical Trials (5)

Total enrollment: 2,451 patients across 5 trials

NCT03564509Ferring PharmaceuticalsFE 999302

A Trial to Investigate the Efficacy and Safety of FE 999302 as add-on Treatment to Follitropin Delta (REKOVELLE) in Women Undergoing Controlled Ovarian Stimulation.

Start: May 2018Est. completion: Jan 2020620 patients
Phase 2Completed
NCT05499052Ferring PharmaceuticalsREKOVELLE®

Trial to Assess the Pattern of Use of REKOVELLE® in Women Undergoing In Vitro Fertilisation (IVF) or Intracytoplasmic Sperm Injection (ICSI) Procedures in Routine Clinical Practice

Start: Aug 2022Est. completion: Mar 2024201 patients
N/ACompleted
NCT04503707Ferring PharmaceuticalsFollitropin Delta

Study to Assess the Design of Use of REKOVELLE® in Women Undergoing In Vitro Fertilisation or Intracytoplasmic Sperm Injection Procedures in Routine Clinical Practice

Start: Jun 2020Est. completion: Oct 2021250 patients
N/ACompleted
NCT03697031Ferring PharmaceuticalsFollitropin Delta

Impact of Blastocyst Morphological Development and Blastocoele Re-expansion on Pregnancy Outcome After Using REKOVELLE®

Start: Sep 2018Est. completion: Dec 2020362 patients
N/ATerminated
NCT03393780Ferring PharmaceuticalsFollitropin Delta

Study to Assess the Patterns of Use of REKOVELLE® in Naïve Women Undergoing In Vitro Fertilisation or Intracytoplasmic Sperm Injection Procedures

Start: Mar 2018Est. completion: Jul 20201,018 patients
N/ACompleted

Related Jobs in Women's Health

Senior Medical Science Liaison

Ferring Pharmaceuticals
Bangkok, Thailand
20h ago

Senior Key Account Manager

Ferring Pharmaceuticals
Bucureşti, Romania
1w ago

Territory Representative - Miami

Caldera Medical
Miami, FL, US
1w ago

Sales Representative Gynecological Health

Medtronic
Malaga, Andalucia, Spain
1w ago

Sales Representative, Women's Health - Charleston, SC

Viatris (2)
Remote
1w ago
$72K - $108K/yr

Sales Representative, Women's Health- Charlotte, NC

Viatris (2)
Remote
1w ago
$72K - $108K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space

Related Indications

Endometriosis(43)Menopause(27)Polycystic Ovary Syndrome(14)Postmenopause(8)Vasomotor Symptoms Associated With Menopause(4)Polycystic Ovarian Syndrome(3)Preeclampsia(3)Uterine Fibroids(3)Uterine Leiomyomata (Fibroids)(3)Ovarian Hyperstimulation Syndrome(3)